Rucaparib (AG-014699,PF-01367338) phosphate

製品コードS1098

Rucaparib (AG-014699,PF-01367338) phosphate化学構造

分子量(MW):421.36

Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay, also showing binding affinity to eight other PARP domains. Phase 3.

サイズ 価格(税別)  
JPY 22244.00
JPY 19920.00
JPY 34860.00
JPY 111220.00

カスタマーフィードバック(6)

  • For anchorage dependent clonogenic assays, HER2+ breast cancer BT474 cells were seeded at low density in 6-well plates and allowed to adhere overnight. The next day, olaparib and rucaparib were added at the indicated concentrations. Media and drugs were replenished every three days. After 10-15 days, depending on cell proliferation rate, cells were fixed and stained with crystal violet. Images and graphs indicate the results compared to control condition. Data are mean ± S.D. n.s.: non-significant, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.

    Eur J Cancer 2014 50(15), 2725-34. Rucaparib (AG-014699,PF-01367338) phosphate purchased from Selleck.

    Total cell extracts of BT-474 cells treated with increasing concentrations of olaparib or rucaparib were subjected to western blot analysis for PARP-1 and poly ADP-ribose (PAR) expression. β-tubulin was used as loading control. Representative images from two separate experiments are shown.

    Eur J Cancer 2014 50(15), 2725-34. Rucaparib (AG-014699,PF-01367338) phosphate purchased from Selleck.

  • purified PARP-1 and His-XPA were incubated alone ( lane 7 ), with activated PARP-1 (addition of activated DNA and NAD+, lane 8 ), or in the presence of the PARP inhibitor AG-014699 (lane 9 ). Following the various treatments, His-XPA was pulled down ( IP ) from each sample using cobalt-conjugated magnetic beads.

    J Biol Chem 2012 287, 39824-33. Rucaparib (AG-014699,PF-01367338) phosphate purchased from Selleck.

    Three sensitive and three resistant cell lines were treated for 24 h with 0.02% DMSO (negative control) or 10 uM rucaparib. Serving as positive control were cells fixed 30 min after exposure to 2 Gy IR. Image acquisition was performed with a confocal microscope (Leica TCS SP2) using the 100X objective and a 2X optical zoom and oil immersion. Red: γH2AX foci. Green: RAD51 foci. *P < 0.05 **P < 0.01 ***P < 0.001. Fluorescence microscopy images of DAPI-stained rucaparib-sensitive (HN4) and rucaparib-resistant (SAS) HNC cell lines treated with DMSO, 2 Gy or 10 uM rucaparib for 24 h.

    Oral Oncol 2014 50(9), 825-31. Rucaparib (AG-014699,PF-01367338) phosphate purchased from Selleck.

  • Antitumor effects of transfecting of INPP4B gene combined with PARP inhibitor treatment on PC3 cells. (A) The change of cell number and shape under the microscope. (B) The viability of PC3 cells measured using CCK-8. (C) The cell cycle phase distribution of PC3 detected by flow cytometry. (D) Apoptosis of PC3 cells detected using annexin V-FITC/PI staining. (Asterisks denote statistical significance between Lenti-INPP4B+PARP inhibitor and Lenti-INPP4B and PARP inhibitor treatment, *P<0.05).

    Urol Oncol 2014 32(5), 720-6. Rucaparib (AG-014699,PF-01367338) phosphate purchased from Selleck.

    in vivo suppression of PAR formation by the PARP inhibitor AG-014699 upon induction of DNA damage

    Primary human lung fibroblast cells (MRC-5) were pre-treated with the indicated concentration of the PARP inhibitor AG-014699 for two hours. Oxidative DNA damage was induced by 500 µM H2O2 for 10 min and cellular PARP activity was measured by immuno-staining of poly(ADP)-ribose (PAR) (right panels). The in vivo effect of PARP inhibition was compared to cells without DNA damage induction and inhibitor (control) and H2O2-treated cells without inhibitor.
    Average nuclear PAR staining intensities of more than 50 cells were statistically analysed by Kruskal-Wallis and the post-hoc Dunn’s Multiple Comparison tests (left panel). Asterisks indicate highly significant (p<1%) differences to H2O2-treated cells without PARP inhibitor. Thick horizontal bars mark medians and error bars the interquartile range.
     
     

     

    Dr. David Schrmann from University of Base. Rucaparib (AG-014699,PF-01367338) phosphate purchased from Selleck.

製品安全説明書

PARP阻害剤の選択性比較

生物活性

製品説明 Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay, also showing binding affinity to eight other PARP domains. Phase 3.
特性 The first PARP inhibitor used in clinical trials combined with temozolomide.
ターゲット
PARP [1]
(Cell-free assay)
1.4 nM(Ki)
体外試験

Rucaparib is a potent inhibitor of purified full-length human PARP-1 and shows higher inhibition of cellular PARP in LoVo and SW620 cells. Besides, Rucaparib binds detectably to eight other PARP domains, including PARP2, 3, 4, 10, 15, 16, TNKS1 and TNKS2. [1] [2] The radio-sensitization by Rucaparib is due to downstream inhibition of activation of NF-κB, and is independent of SSB repair inhibition. Rucaparib could target NF-κB activated by DNA damage and overcome toxicity observed with classical NF-κB inhibitors without compromising other vital inflammatory functions. [3] Rucaparib inhibits PARP-1 activity by 97.1% at a concentration of 1 μM in permeabilised D283Med cells. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BT-474 NWHIbXNnTnWwY4Tpc44hSXO|YYm= M3i5XFAvOS9zL{WwNE8yODByIH7N MWHpcohq[mm2czDQRXJRKGGldHn2bZR6KGG2IIP0ZZJ1cW6pIHPvcoNmem62cnH0bY9vKG:oIEWwNEBvVQ>? NVrEWWNGOjVzMki0OVU>
BT474 NWfJfWhFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvxVWtpPTByIH7N Mn7DNVDjiJNzNdMg[C=> NWfXToFRemWmdXPld{Bk\WyuIHfyc5d1cCCrbjD0bIUh\m:3cjDsbY5meyCjbnSgd4lodmmoaXPhcpRtgQ>? NUHCZ3VpOjVzMki0OVU>
SKBR3 NGPGTZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DXelUxOCCwTR?= NFHUcVcyOOLCk{G1xsBl M{XQVZJm\HWlZYOgZ4VtdCCpcn;3eIghcW5idHjlJIZwfXJibHnu[ZMh[W6mIIPp[45q\mmlYX70cJk> NV\uNXZ2OjVzMki0OVU>
AU565 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYG1NFAhdk1? M3fqT|Ex6oDVMUZCpIQ> NHzveZVz\WS3Y3XzJINmdGxiZ4Lve5RpKGmwIITo[UBnd3W{IHzpcoV{KGGwZDDzbYdvcW[rY3HueIx6 Mo\mNlUyOjh2NUW=
EFM192A NU\UNXh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmK1OVAxKG6P MmjmNVDjiJNzNdMg[C=> MmPOdoVlfWOnczDj[YxtKGe{b4f0bEBqdiC2aHWg[o92eiCuaX7ld{BidmRic3nncolncWOjboTsfS=> M3;kXVI2OTJ6NEW1
MDA-MB-231 NUTjfWVHTnWwY4Tpc44hSXO|YYm= MmfhNVAwOjBxNECg{txO NXLveolnOjRiaB?= NWiw[|U2cW6lcnXhd4V{KHBvQVvUJIxmfmWuczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MonGNlQ1OjBzNUK=
MDA-MB-231 NYrCRZRSS2WubDDWbYFjcWyrdImgRZN{[Xl? NHu1O|gxNjFvNECg{txO Mof3NlQhcA>? Ml\XTWM2OOLCiU5ihKkyPy55N9Mg{txO Moe1NlQ1OjBzNUK=
MDA-MB-231 NWO2WldFSXCxcITvd4l{KEG|c3H5 MlexNVAwOjBxNECg{txO NHzXepEzPCCq NUnGWpQzcW6mdXPld{BieG:ydH;zbZMh\G:|ZTDk[ZBmdmSnboTsfS=> NULWbVdROjR2MkCxOVI>
MDA-MB-231 MojsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjNelV1OTBxMkCvOFAh|ryP NF7KWo8zPCCq NGe2OWNjdG:la4OgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCrbjDHNk9OKHCqYYPl M3PTVVI1PDJyMUWy
H460 M3vNZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYi0NFAhdk1? MV:yOOKhcA>? MXjpcoNz\WG|ZYOgZ4VtdHWuYYKgdoFlcW:|ZX7zbZRqfmm2eR?= M33ZZlI1PDFzNkGx
A549  NWDPPGJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TNTFQxOCCwTR?= NVnF[VVnOjUEoHi= M2XGe4lv[3KnYYPld{Bk\WyudXzhdkBz[WSrb4PlcpNqfGm4aYT5 NVPncoZHOjR2MUG2NVE>
DT40 NGD3eYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE[3NINKSzVyPUKxJI5O NFHiOG8zPDN3NkixNy=>
DU145 NWDNd3hKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofQTWM2OD1zODDuUS=> NFnvS2IzPDN3NkixNy=>
COLO704 MkjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\Pc4VKSzVyPUKuOVIhyrFiMD62O{DPxE1? Mn;KNlM4Ojl2MEK=
OVMANAb M4C4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HrVmlEPTB;Mj61PEDDuSByLkO4JO69VQ>? NULYWWI2OjN5Mkm0NFI>
OV177 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXSxb2JSUUN3ME2yMlc5KMLzIECuO|Eh|ryP NYeyU2JWOjN5Mkm0NFI>
OAW28 MlnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\5TWM2OD1|Lk[xJOKyKDBwMkig{txO MYmyN|czQTRyMh?=
OVSAHO M3fIfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\VTWM2OD1|Lk[0JOKyKDBwM{Og{txO MmPVNlM4Ojl2MEK=
OVKATE M3:yfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTvTWM2OD1|Lk[0JOKyKDFwN{mg{txO NGS4VlkzOzd{OUSwNi=>
OVCAR3 MnLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jGR2lEPTB;Mz63OEDDuSByLkSwJO69VQ>? NV7yfIZCOjN5Mkm0NFI>
PEO14 NWLiSIRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\JWWNKSzVyPUOuPFQhyrFiMD63OkDPxE1? MnHlNlM4Ojl2MEK=
A2780 NGrSbYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzhbFJyUUN3ME2zMlk1KMLzIECuNlUh|ryP NGXpT|czOzd{OUSwNi=>
OVTOKO MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYj6[5h2UUN3ME20MlE1KMLzIEGuOVMh|ryP NVLXWplCOjN5Mkm0NFI>
KURAMOCHIb NIXxZ3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfVcYlKSzVyPUSuN|QhyrFiMD6yPUDPxE1? MnXSNlM4Ojl2MEK=
TOV21G NWfwWXZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HPbGlEPTB;NT6wO{DDuSBzLkOwJO69VQ>? NUXmOW5yOjN5Mkm0NFI>
OVISE Mlu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTVwNkigxtEhOC5{MzFOwG0> NX\uWm1QOjN5Mkm0NFI>
KK MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHe4RnBKSzVyPU[uNVUhyrFiMT60NkDPxE1? NVvHV3F7OjN5Mkm0NFI>
RMUGS NEH1fVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\NXmdKSzVyPUeuNFMhyrFiMT64N{DPxE1? MU[yN|czQTRyMh?=
PEO6 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2eyXWlEPTB;Nz6wOkDDuSByLke0JO69VQ>? MlL5NlM4Ojl2MEK=
OVCA429 M2rlZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjhfGVKSzVyPUiuNlkhyrFiMT62OEDPxE1? MWiyN|czQTRyMh?=
OV167 NITkNItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjOTWM2OD16LkOzJOKyKDFwMUig{txO MX:yN|czQTRyMh?=
RMG1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDOTWM2OD17LkOyJOKyKDJwM{[g{txO MlPJNlM4Ojl2MEK=
OVCAR5 NHHqTWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTlwNUCgxtEhOi53OTFOwG0> MkjVNlM4Ojl2MEK=
EFO21 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3[wWmlEPTB;OT65NkDDuSBzLki3JO69VQ>? M4\wR|I{PzJ7NECy
ES2 NH7WUIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrPOnI3UUN3ME2xNE4yOiEEsTCxMlI{KM7:TR?= NHL2N5QzOzd{OUSwNi=>
Tyk-nu NGniOHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTFyLkKwJOKyKDFwMUKg{txO NG\rO4YzOzd{OUSwNi=>
CAOV3 NISzV4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XGRmlEPTB;MUCuN|chyrFiMD64O{DPxE1? MkfaNlM4Ojl2MEK=
OV207 M3f3Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYizTJhGUUN3ME2xNk4zPyEEsTCwMlMzKM7:TR?= NX\ifnJ6OjN5Mkm0NFI>
HEY NGroOY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPDTWM2OD1zMz6wNUDDuSByLke1JO69VQ>? MmrONlM4Ojl2MEK=
DOV13 NV3Oc3FZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;ETWM2OD5zNTFOwG0> NFvqTHczOzd{OUSwNi=>
EFO27 MmD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\BRWlEPTB-MUWg{txO NYr1OmM4OjN5Mkm0NFI>
HEY C2 NF3xdlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfLUpVKSzVyPkG1JO69VQ>? MnLONlM4Ojl2MEK=
KOC-7cc M3HxXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYWzVG5xUUN3ME6xOUDPxE1? NGHlPZQzOzd{OUSwNi=>
MCASb M{X2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInOXnBKSzVyPkG1JO69VQ>? NF;scnQzOzd{OUSwNi=>
OAW42 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXSTWM2OD5zNTFOwG0> MWGyN|czQTRyMh?=
OV2008 M1LDXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfS[IVEUUN3ME6xOUDPxE1? MWCyN|czQTRyMh?=
OV90 NIezfmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXrSZA{UUN3ME6xOUDPxE1? M4XocVI{PzJ7NECy
OVCA420b MojRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTT[VZ{UUN3ME6xOUDPxE1? MlzxNlM4Ojl2MEK=
OVCA432 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfHVXJKSzVyPkG1JO69VQ>? MmPmNlM4Ojl2MEK=
PEA2 NGLTcmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEi5S3BKSzVyPkG1JO69VQ>? M2Ky[FI{PzJ7NECy
SKOV3 NYDvO5VrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRjF3IN88US=> NYLjdYtUOjN5Mkm0NFI>
TOV112D NFH6NppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWKwMVMh|ryP NFvqWnZKSzVyPkG1JO69VQ>? NX;CTHJTOjN5Mkm0NFI>
C4-2 NFLOVVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DsXFAuOyEQvF2= M3HCSFE1KGR? NGjqZYVFVVOR NVq4bVFI\GWlcnXhd4V{KGOxbH;ufUBvfW2kZYKg[I9{\SCmZYDlcoRmdnSueR?= NF\wb5kzOzV4NUK0OC=>
PC3 NVmyTHo6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYiwMVMh|ryP NFHCOJEyPCCm NHPKcGRFVVOR NVO1PWpP\GWlcnXhd4V{KGOxbH;ufUBvfW2kZYKg[I9{\SCmZYDlcoRmdnSueR?= NXziS4dIOjN3NkWyOFQ>
DU145 NGDvTZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzSS2VPOC1|IN88US=> M17IfFE1KGR? NX25[3Q2TE2VTx?= M1f2VIRm[3KnYYPld{Bkd2yxbomgcpVu[mW{IHTvd4Uh\GWyZX7k[Y51dHl? MWSyN|U3PTJ2NB?=
VCaP  M4\IOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvBNE0{KM7:TR?= NHLSb2syPCCm MoTDSG1UVw>? M{HPRoRm[3KnYYPld{Bkd2yxbomgcpVu[mW{IHTvd4Uh\GWyZX7k[Y51dHl? NYfaSHNROjN3NkWyOFQ>
LNCaP  M2fwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzRNE0{KM7:TR?= M4\j[FE1KGR? NHfVbmdFVVOR NFnObZBl\WO{ZXHz[ZMh[2:ub375JI52dWKncjDkc5NmKGSncHXu[IVvfGy7 MWmyN|U3PTJ2NB?=
MDA-MB-468 NVWyUGVKS2WubDDWbYFjcWyrdImgRZN{[Xl? MmrUTWM2OD17Lkeg{txO NUHUdnVzOjJ4N{ixOlE>
MDA-MB-231 M1X0SWNmdGxiVnnhZoltcXS7IFHzd4F6 NFXVWplKSzVyPUGzJO69VQ>? MWmyNlY4QDF4MR?=
Cal-51 MWfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M3fnOGlEPTB;OD62JO69VQ>? NYjTZ4pPOjJ4N{ixOlE>

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Rucaparib is not toxic but significantly enhances temozolomide-induced TGD in the DNA repair protein-competent D384Med xenografts. Pharmacokinetics studies also show that Rucaparib is detected in the brain tissue, which indicates that Rucaparib has potential in intra-cranial malignancy therapy. [4] Rucaparib significantly potentiates the cytotoxicity of topotecan and temozolomide in NB-1691, SH-SY-5Y, and SKNBE (2c) cells. Rucaparib enhances the antitumor activity of temozolomide and indicates complete and sustained tumor regression in NB1691 and SHSY5Y xenografts. [5]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
+ 展開

Ki Determination:

Inhibition of human full-length recombinant PARP-1 by [32P]NAD+ incorporation is measured. The [32P]ADP-ribose incorporated into acid insoluble material is quantified using a PhosphorImager. Ki is calculated by nonlinear regression analysis.
細胞試験: [4]
+ 展開
  • 細胞株: D425Med, D283Med and D384Med cells
  • 濃度: 0.4 μM
  • 反応時間: 3 or 5 days
  • 実験の流れ: Medulloblastoma cell lines are seeded in 96-well plates at a density of 1 × 103, 3 × 103 and 3 × 103, respectively. At 24 hours (D384Med) or 48 hours (D283Med and D425Med) after seeding, the cells are exposed to various concentrations of temozolomide in the presence or absence of 0.4 μM Rucaparib. After 3 days (D425Med and D384Med) or 5 days (D283Med) of culture, cell viability is evaluated by a XTT cell proliferation kit assay. Cell growth is expressed as a percentage in relation to DMSO or 0.4 μM Rucaparib-alone controls. The concentration of temozolomide, alone or in combination with Rucaparib that inhibited growth by 50% (GI50) is calculated. The potentiation factor 50 (PF50) is defined as the ratio of the GI50 of temozolomide in the presence of Rucaparib to the GI50 of temozolomide alone.
    (参考用のみ)
動物試験:[4]
+ 展開
  • 動物モデル: CD-1 nude mice bearing established D283Med xenografts
  • 製剤: Normal saline
  • 投薬量: 1 mg/kg
  • 投与方法: One or four daily by i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 84 mg/mL (199.35 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます:
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
10mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 421.36
化学式

C19H18FN3O.H3PO4

CAS No. 459868-92-9
保管
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02975934 Recruiting Metastatic Castration Resistant Prostate Cancer Clovis Oncology, Inc.|Foundation Medicine January 2017 Phase 3
NCT02986100 Recruiting Solid Tumor Clovis Oncology, Inc. November 2016 Phase 1
NCT02952534 Recruiting Metastatic Castration Resistant Prostate Cancer Clovis Oncology, Inc.|Foundation Medicine November 2016 Phase 2
NCT02855944 Recruiting Ovarian Cancer|Epithelial Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer Clovis Oncology, Inc.|Foundation Medicine September 2016 Phase 3
NCT02740712 Recruiting Neoplasms Clovis Oncology, Inc. March 2016 Phase 1
NCT02505048 Recruiting Metastatic Breast Cancer UNICANCER|Clovis Oncology, Inc.|Fondation ARC March 2016 Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

PARPシグナル伝達経路

PARP Inhibitors with Unique Features

相関PARP製品

Tags: Rucaparib (AG-014699,PF-01367338) phosphateを買う | Rucaparib (AG-014699,PF-01367338) phosphate ic50 | Rucaparib (AG-014699,PF-01367338) phosphate供給者 | Rucaparib (AG-014699,PF-01367338) phosphateを購入する | Rucaparib (AG-014699,PF-01367338) phosphate費用 | Rucaparib (AG-014699,PF-01367338) phosphate生産者 | オーダーRucaparib (AG-014699,PF-01367338) phosphate | Rucaparib (AG-014699,PF-01367338) phosphate化学構造 | Rucaparib (AG-014699,PF-01367338) phosphate分子量 | Rucaparib (AG-014699,PF-01367338) phosphate代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID